Apollo Endosurgery, Inc.
APEN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.52 | 0.60 | 0.16 | 0.05 |
| FCF Yield | -8.39% | -6.24% | -27.71% | -43.33% |
| EV / EBITDA | -12.90 | -15.35 | -8.33 | -3.26 |
| Quality | ||||
| ROIC | -30.59% | -16.32% | -23.55% | -50.94% |
| Gross Margin | 55.20% | 55.50% | 52.90% | 50.63% |
| Cash Conversion Ratio | 0.78 | 0.59 | 0.92 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.27% | 7.49% | -11.59% | -7.61% |
| Free Cash Flow Growth | -113.75% | 25.80% | 19.40% | -2.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.00 | 2.62 | -1.82 | -0.92 |
| Interest Coverage | -5.96 | -2.31 | -3.01 | -7.19 |
| Efficiency | ||||
| Inventory Turnover | 1.89 | 2.34 | 1.92 | 2.82 |
| Cash Conversion Cycle | 185.98 | 154.53 | 193.54 | 51.33 |